Ongoing research within the advanced-stage melanoma therapeutic space is beginning to suggest that shorter treatment periods may be sufficient for some. Ongoing research within the advanced-stage ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

The News On 6 weekend team provides a comprehensive look at updated news events, a detailed and up-to-the-minute weather forecast, and the latest sports highlights. TULSA, Okla. - The FDA has approved ...

Whether it’s for fun or for work, we’ve all spent too much time in the sun, but did you know that too much sun is the leading cause of melanoma? Melanoma is a type of aggressive skin cancer that is ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

ORLANDO, Fla. (Ivanhoe Newswire) - Melanoma, it’s a type of aggressive skin cancer that is the fifth most deadly cancer. Surgery, immunotherapy, and chemo are the typical treatments. But now, the FDA ...

Loqtorzi (toripalimab) showed significant improvement in progression-free survival for acral melanoma compared to standard chemotherapy in a phase 3 trial. Acral melanoma, a rare and aggressive ...

SCIB1/iSCIB1+ combined with checkpoint inhibitors shows improved response rates and progression-free survival in advanced melanoma without added toxicity. The SCOPE trial's findings suggest a ...

The FDA has approved a groundbreaking therapy for patients with late-stage melanoma. Melanoma is an aggressive skin cancer that's the fifth most deadly. Too much sun is the leading cause of skin ...